Dr. Mauricio Augusto Riofrío Riofrío

Oncólogo Clinico

Teléfonos: 04-6005681/  099 929 8384

E-mail: m_riofrio@hotmail.com

Experiencia Laboral

  • 1985-1991: Medical Studies at Catholic University of Guayaquil.
  • 1991-1992: Pregrade Practice at Social Security Hospital and Alejandro’s MANN Child Hospital, Guayaquil – Ecuador
  • 1992: Internal Medicine and Surgery Doctoral Degree of the Ecuadorian Republic.
  • 1992-1993: Medical Community Practice for the Ecuadorian Public Health Minister.
  • 1993-1996: Resident at Internal Medicine Department of M.H.Alcívar Hospital.
  • 1994-1996: Practice Professor of Clinical Oncology at Catholic University of Guayaquil.
  • 1994-1996: Fellow of Internal Medicine Department at National Ecuadorian Cancer Institute, SOLCA Guayaquil
  • 1996-1997: Foreign Resident of Paris Medical College.
  • 1997-1998: Resident of the Hematology, Immunology and Tumoral Disease Department at Paul Brousse Hospital (Villejuif).
  • 1998: « Certificat C2 Regulations Cellulairs, Pathologie des Regulations» Biology and Medical Sciences Matrix.
  • 1998: Certification of Specialist Formation in Clinical Oncology delivered by the Paris XI University.
  • Feb 1999-October 2000: Senior Resident of Medicin Department at Gustave Roussy Institut.
  • November 2000-October 2001: Chef de Clinique at Oncologist and Hematologist Service of Paul Brousse Hospital, Paris XI University
  • 1999-2001: ESMO (European Society of Medical Oncology) Fellowship winner.
  • August 2002-October 2012 Head of Clinical Oncology Service at Hospital Naval Guayaquil
  • Since November 2012 Head of Clinical Oncology Service at M.H. Alcivar Hospital

Publications and Posters

  • Cervix Carcinoma, In Situ and IA Stade, prognostic and treatment. Oral presentation VII Ecuadorian National Congress of Cancerology, Guayaquil July 1992.
  • Invaginación intestinal diagnosticada y reducida por enema baritado. Actas Médicas; Vol. 4 No. 1, 1994 pag.57-61.
  • Infarto agudo de miocardio, estudio de 4 años en la unidad de terapia intensiva del Hospital M.H. Alcivar. Actas Médicas; Vol. 4 No. 1, 1994 pag. 90-96.
  • Paludismo y derrame pleural, estudio de 2 casos. Actas Médicas; Vol. 4 No. 2, 1994 pag. 144-148.
  • Valeur predictive du taux initial de bilirubinemie et de son elevation precoce et transitoire au cours des chimiotherapies comportant du CPT-11, dans la survenue de neutropenie et diarrhee severes. Poster discution XVIIeme Forum de Cancerologie, Paris Mai 1997.
  • Bilirubin: Baseline value and transient increase of total bilirubin (BIL) may be used as good predictor of CPT-11’s toxicity. Oral presentation ECCO 9 Hamburg September 1997.
  • Oxaliplatin (L-OHP)/CPT11 combination every two weeks: Preliminary results of a phase I study in advanced digestive malignancies. Poster presentation at AACR eighty-ninth Annual Meeting New Orleans, LA – March 1998.
  • Ecteinascidin-743 (ET-743) 24 hours continuous intravenous infusion (CI) phase I study in solid tumors (ST) patients (pts). Poster presentation at AACR eighty-ninth Annual Meeting New Orleans, LA – March 1998.
  • Baseline serum bilirubin, a good predictor of CPT-11 neutropenia. A pharmacokinetic/Pharmacodynamic (pk/pd) correlation. Poster presentation at AACR eighty-ninth Annual Meeting New Orleans, LA – March 1998.
  • Bilirubin (BIL) and SN-38 Metabolism: Pharmacodynamics of CPT-11 Toxicity. Proceedings of ASCO Thirty-fourth Annual Meeting. May 1998 Los Angeles, CA.
  • Ecteinascidin-743 (ET-743) 24 hours continuous infusion (CI): Clinical and pharmacokinetic phase I study in solid tumor patients (PTS). Preliminary results. Poster presentation ASCO Thirty-fourth Annual Meeting. May 1998 Los Angeles, CA.
  • CPT11/Oxaliplatin (L-OHP) every two weeks: A phase I study in patients (PTS) with advanced digestive tumors. Poster presentation ASCO Thirty-fourth Annual Meeting. May 1998 Los Angeles, CA.
  • CPT11/Oxaliplatin (L-OHP): Thimidylate sinthase (TS) independent combination with efficacy in 5-FU refractory colorectal cancer (CRC) patients (PTS). Poster presentation ASCO Thirty-fourth Annual Meeting. May 1998 Los Angeles, CA.
  • Bilirubin (BIL) and SN-38: Pharmacokinetic/Pharmacodynamics correlation. Poster presentation at 10 th NCI-EORTC symposium on new drugs in cancer therapy. June 1998 Amsterdam.
  • Ecteinascidin-743 (ET-743) 24-hour continuous intravenous infusion (CI) phase I study in solid tumors (ST) patients. Poster presentation at 10 th NCI-EORTC symposium on new drugs in cancer therapy. June 1998 Amsterdam.
  • CPT-11/oxaliplatin (L-OHP) combination: Comparison of the toxicity of two schedules of administration. Poster presentation at 10 th NCI-EORTC symposium on new drugs in cancer therapy. June 1998 Amsterdam.
  • Oxaliplatin (L-OHP)/CPT 11 combination every two weeks. Results of an ongoing phase I study in advanced digestive malignancies. Poster presentation ESMO 23rd congress, November 1998 – Athens, Greece.
  • Ecteinascidin-743 (ET-743) 24 hours continuous infusion (CI): Clinical and pharmacokinetic phase I study progressive report. Poster presentation ESMO 23rd congress, November 1998 – Athens, Greece.
  • Ecteinascidin-743(ET- 743) 24 hours continuous infusion (CI): Clinical and pharmacokinetic phase I study, final report. Poster presentation ASCO Thirty-fifth annual meeting. May 1999 Atlanta GA.
  • Facteurs Pronostics du Cancer du Sein et Facteurs Prédictifs de la Reponse au Traitement. La Lettre du Cancérologue ; Fevrier 2000, Vol. IX n° 1, pag. 29-35. 3.
  • Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.J Clin Oncol. 2001 Mar 1;19(5):1256-65.
  • Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients–preliminary evidence of activity.J Clin Oncol. 2001 Mar 1;19(5):1248-55.
  • Single-agent estramustine phosphate (EMP) is active in advanced breast cancer after failure with anthracyclines and taxanes.Ann Oncol. 2001 Sep;12(9):1265-8.
  • Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma.Cancer. 2001 Nov 1;92(9):2267-72.
  • Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.J Clin Oncol. 2004 Mar 1;22(5):890-9.
  • A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer.Br J Cancer. 2006 Jun 5;94(11):1610-4.